(Q80487606)
Statements
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial (English)
Samir S Taneja
Neil Fleshner
Leonard G Gomella
Michael S Cookson
Antonio Finelli
Andrew Evans
M Scott Lucia
Eric Wolford
Matthew C Somerville
Roger Rittmaster
REDEEM Study Group